Evaluation of A Marketed Silicone Hydrogel Spherical Lens Used for Monovision Correction of Presbyopia

Not Applicable

Completed

• Conditions: Visual Acuity
• Interventions: Device: ACUVUE® OASYS with Transitions™

• Registration Number: NCT04073186
• Lead Sponsor: Johnson & Johnson Vision Care, Inc.

Brief Summary

This is a single-masked, dispensing clinical trial. A total of approximately 48 myopic and 32 hyperopic eligible subjects will be targeted to complete the study. Subjects will be fit in the study lens, optimized if required and worn for approximately 2 weeks. Subjects will then have a washout period of approximately 1 week and be refit in the lenses and be dispensed for an additional 2 weeks of wear.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-08-07
• Study First Submitted: 2019-08-28
• Study First Submitted QC: 2019-08-28
• Study First Posted: 2019-08-29
• Primary Completion: 2020-03-20
• Study Completion: 2020-03-20
• Results First Submitted: 2021-03-19
• Results First Submitted QC: 2021-04-26
• Results First Posted: 2021-05-18
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-08
• Last Update Posted: 2022-08-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 91

Inclusion Criteria

• Potential subjects must satisfy all the following criteria to be enrolled in the study:

  1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  2. The subject must appear able and willing to adhere to the instructions set forth in this clinical protocol.
  3. The subject must be between 40 and 70 years of age at the time of screening.
  4. Subjects must own a wearable pair of spectacles if required for their distance vision.
  5. The subject must be an adapted monovision soft contact lens wearer in both eyes (i.e., worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month of more duration).
  6. The subject's distance spherical equivalent refraction must be in the range of +3.50 D to -4.00 D in each eye.
  7. The subject's refractive cylinder must be ≤1.00 D in each eye.
  8. The subject's ADD power must be in the range of +0.75 D to +2.50 D.
  9. The subject must have best corrected distance visual acuity of 20/20-3 or better in each eye.

Exclusion Criteria

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:

  1. Currently Pregnant or lactating.
  2. Any active or ongoing systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear. This may include, but not be limited to, diabetes, hyperthyroidism, recurrent herpes simplex/zoster, Sjögren's syndrome, xerophthalmia, acne rosacea, Stevens-Johnson syndrome, and immunosuppressive diseases or any infectious diseases (e.g., hepatitis, tuberculosis).
  3. Use of any of the following medications within 1 week prior to enrollment: oral retinoid isotretinoin (e.g. Accutane), oral tetracyclines, oral phenothiazines (e.g., Haldol, Mellaril, Thorazine, Elavil, Pamelor, Compazine), systemic steroids.
  4. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, dacryocystorhinostomy, etc.).
  5. Use of any ocular medication, with the exception of rewetting drops.
  6. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.
  7. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
  8. Any known hypersensitivity or allergic reaction to OPTI-FREE® Puremoist® care cleaning solution, non-preserved rewetting drop solution or sodium fluorescein.
  9. History of herpetic keratitis.
  10. Entropion, ectropion, chalazia, glaucoma, history of recurrent corneal erosions.
  11. A history of amblyopia, strabismus or binocular vision abnormality.
  12. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corneal staining, tarsal abnormalities or bulbar injection, or any other corneal or ocular abnormalities which would contraindicate contact lens wear.
  13. Any ocular infection or inflammation.
  14. Any ocular abnormality that may interfere with contact lens wear.
  15. Any active or ongoing ocular or systemic allergies that may interfere with contact lens wear.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ACUVUE® OASYS with Transitions™	ACUVUE® OASYS with Transitions™	Eligible subjects between the ages of 40 to 70 years of age and habitual wearers of soft contact lenses will be fitted with the study lens for two wearing cycles.

Primary Outcome Measures

Name	Time	Method
Vision Scores	2-Week Follow-up	Vision Scores were assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
Visual Performance (logMAR)	2-Week Follow-up	Binocular visual performance on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters), intermediate (64 centimeters) and near (40 centimeters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. The room illuminance was required to be etween 7.3 and 7.9 EV (394-597 lux). For Distance (4 meters), the acceptable range for the chart luminance was 10.5-10.7 EV (181-208 cd/m2). For Intermediate (64 cm) and Near (40cm), the acceptable range for the chart luminance 10.8-11.1 EV (223-274 cd/m2).; Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. A logMAR visual performance score of 0.0 is equivalent to Snellen visual acuity of 20/20.

Secondary Outcome Measures

Name	Time	Method
CLUE Vision Comparison Between First Wearing Cycle and Second Wearing Cycle	Up to 2-Week Follow-up	Vision Scores wwere assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Trial Locations

Locations (5)

Western Reserve Vision Care, Inc.; 🇺🇸 Beachwood, Ohio, United States

VRC-East; 🇺🇸 Jacksonville, Florida, United States

Advanced Eyecare; 🇺🇸 Raytown, Missouri, United States

Dr. David W. Ferris & Associates; 🇺🇸 Warwick, Rhode Island, United States

Manhattan Vision Associates; 🇺🇸 New York, New York, United States